Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Dai-ichi Life Holdings (DCNSF – Research Report) received a Hold rating and a Yen4,900.00 price target from Jefferies analyst Sam Wong on March 7. The company’s shares closed last Friday at ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

(Bloomberg) -- Dai-ichi Life Holdings Inc. said a US subsidiary agreed to transfer insurance blocks totaling about $9.7 billion in policy reserves to a reinsurance firm to improve earnings. Protective ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Curse is a dark dungeon RPG centered around the concept of curses. The player takes on the role of an adventurer tasked with saving a town plagued by a curse, while exploring dungeons filled with ...